Drug Patent & Exclusivity Expiration Report - Week of April 21 2025 2025-04-21
This week, there are 18 drugs in the patent and exclusivity list. They are: - VIIV HEALTHCARE CO's JULUCA, containing active ingredient DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JANSSEN PRODUCTS LP's EDURANT, containing active ingredient RILPIVIRINE HYDROCHLORIDE - GILEAD SCIENCES INC's ODEFSEY, containing active ingredient EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - VIIV HEALTHCARE CO's CABENUVA KIT, containing active ingredient CABOTEGRAVIR; RILPIVIRINE - GILEAD SCIENCES INC's COMPLERA, containing active ingredient EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - CELATOR PHARMACEUTICALS INC's VYXEOS, containing active ingredient CYTARABINE; DAUNORUBICIN - AVEO PHARMACEUTICALS INC's FOTIVDA, containing active ingredient TIVOZANIB HYDROCHLORIDE - GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND's ANORO ELLIPTA, containing active ingredient UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE
Read More